TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.
Home > ÀüÁ¦Ç°º¸±â > PCR > PCR Enzyme (Clontech) > [Cancer Research] Cancer biomarker quantification

[Cancer Research] Cancer biomarker quantification

-



´Ù¾çÇÑ biomarker panel°ú ¿¬±¸

¸¹Àº Ÿ°ÙÀ» ºü¸£°í ¹Î°¨ÇÏ°Ô ºÐ¼®Çϱâ À§ÇØ, ´ÙÄ«¶ó¹ÙÀÌ¿À´Â ´ë·® (High-throughput) qPCRÀ» À§ÇÑ SmartChip¢â SystemÀ» Áö¿øÇÏ°í ÀÖ´Ù.

º» Á¦Ç°Àº ´Ù¾çÇÑ ¿¬±¸¿¡¼­ °¢°¢ÀÇ Áúº´ÀÌ °¡Áö´Â °íÀ¯ÇÑ biomarker¿Í ±× º¯È­¸¦ ´ë·® ºÐ¼®Çϴµ¥ ÀÌ¿ëµÇ¾úÀ¸¸ç, ÀÌ´Â mRNA, miRNA, IncRNA ºÐ¼®¿ë panelÀ» µðÀÚÀÎÇÏ°í È°¿ëÇÒ ¼ö ÀÖ´Ù.


High-throughput studies
¸î¸î ¿¬±¸¿¡¼­´Â human oncology panelÀ» È°¿ëÇÏ¿©, 1,200°³ÀÇ Æ¯ÀÌÀû À¯ÀüÀÚ¸¦ ºÐ¼®ÇÏ¿© 16 ±×·ìÀ¸·Î ºÐ·ùÇÏ¿´´Ù. (signal transduction, cancer, apoptosis, angiogenesis, cardiovascular disease, ADME (toxicology, drug metabolism, and transport), inflammation, kinases, transcription factors, drug targets, G-protein coupled receptors, cell cycle and proliferation, DNA damage repair, growth factors, proteinases, phosphatases)
±× Áß ÇÑ ¿¬±¸¿¡¼­´Â ÀÌ human oncology panelÀ» ÀÌ¿ëÇÏ¿©, human cytomegalovirus (HCMV)¿Í ¾Ï°úÀÇ »óÈ£ÀÛ¿ëÀ» ºÐ¼®ÇÔÀ¸·Î½á, ½ÅÈ£ Àü´Þ (MAPK, PI3K/Akt)°ú °¨¿°, Ç÷°ü ½Å»ý, Á¾¾ç ¾ïÁ¦, DNA ¼Õ»ó º¹±¸ °æ·Î µîÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ °æ·Î¿¡¼­ ¹ßÇöµÇ´Â 20°³ÀÇ À¯ÀüÀÚ¸¦ ¹ß°ßÇÏ¿´´Ù. À̸¦ ÅëÇØ, HCMV°¡ °Ç°­ÇÑ Á¤»ó ¼¼Æ÷¿¡¼­ ¾ÏÀ̳ª Á¾¾ç È°¼ºÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù´Â °¡´É¼ºÀ» È®ÀÎÇÏ¿´´Ù. ¶Ç ´Ù¸¥ ¿¬±¸¿¡¼­´Â µ¿ÀÏÇÑ panelÀ» ÀÌ¿ëÇØ, ´Ü¹éÁú ÇÕ¼º¿¡ »óÈ£ÀÛ¿ëÇÏ´Â ÀÎÀÚÀÎ tyrosyl-tRNA synthetase°¡ ÇÙ¿¡ À§Ä¡ÇÏ¿© DNA ¼Õ»ó º¹±¸ À¯ÀüÀÚ¸¦ Á¶ÀýÇÏ´Â ¹æ¹ý¿¡ ´ëÇØ ºÐ¼®ÇÏ¿´´Ù.
´Ù¸¥ ¿¬±¸¿¡¼­´Â È®ÀÎµÈ 1,306°³ÀÇ miRNA¸¦ Æ÷ÇÔÇÏ´Â miRNA panel°ú SmartChip¢â systemÀ» ÀÌ¿ëÇÏ¿©, ȯÀڷκÎÅÍ ¾òÀº ¼ö¸¹Àº ´ëÀå¾Ï ¼¼Æ÷¿Í ÃéÀå °ü¼±¾Ï ¼¼Æ÷ (pancreatic ductal adenocarcinoma cell) »ùÇ÷κÎÅÍ miRNA¸¦ ¼±º°ÇÔÀ¸·Î½á Áúº´¿¡ °ü¿©ÇÏ´Â ÁÖ¿ä miRNA ¸Å°³Ã¼¸¦ È®ÀÎÇÏ¿´´Ù. ÀÌ panelÀº ¾Ï ¿Ü¿¡µµ ºñħ½ÀÀû »ùÇÃÀ» ÀÌ¿ëÇÑ »êÀü À¯ÀüÀÚ °Ë»ç¿¡ È°¿ëµÉ ¼ö ÀÖÀ¸¸ç, »ê¸ð Ç÷ÀåÀ¸·ÎºÎÅÍ ´Ù¿î ÁõÈıº°ú ¿¬°üµÈ miRNA¸¦ È®ÀÎÇϴµ¥ Àû¿ëµÈ ¹Ù ÀÖ´Ù. ¶ÇÇÑ, miRNA panelÀº °¢±â ´Ù¸¥ ¼¼Æ÷ Áý´Ü¸¦ ¿¬±¸ÇÏ°í Ư¡À» È®ÀÎÇϴµ¥ ÀÌ¿ëÇÒ ¼ö ÀÖ¾î, ÇÑ ¿¬±¸¿¡¼­´Â ¾Ï¼¼Æ÷¿Í Áٱ⼼Æ÷ °£ÀÇ ¼¼Æ÷ »ç¸êÀ» Á¶ÀýÇÏ´Â °øÅëµÈ miRNA¸¦ È®ÀÎÇÏ¿´´Ù. À̻Ӹ¸ ¾Æ´Ï¶ó, ÇÑ ¿¬±¸¿¡¼­´Â Ç÷û, Ç÷Àå, ¹éÇ÷±¸¿¡¼­ÀÇ miRNA ÇÏÀ§ ±×·ì¿¡ ´ëÇÑ Æ¯Â¡À» ºÐ¼®ÇÏ¿´À¸¸ç, ´Ù¸¥ ¿¬±¸¿¡¼­´Â SmartChip¢â systemÀ» ÀÌ¿ëÇÏ¿© miRNA-98¿¡ ÀÇÁ¸ÇÏ´Â T ¼¼Æ÷ÀÇ glucocorticoid ¾ïÁ¦ ÀÛ¿ë¿¡ ´ëÇØ È®ÀÎÇÏ¿´´Ù.
SmartChip¢â system¿¡¼­ panelÀ» ÀÌ¿ëÇØ 1,700°³ÀÇ assay·Î IncRNA¸¦ ¿¬±¸ÇÑ °æ¿ìµµ ÀÖ´Ù. ÀÌ panelÀº Biogazelle¿Í °øµ¿À¸·Î °³¹ßµÇ¾úÀ¸¸ç, °Ô³ð µ¥ÀÌÅͺ£À̽º¿Í ´ëÁ¶ÇØ, Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) °¡À̵å¶óÀο¡ ÁؼöÇÏ¿© Á¦À۵Ǿú´Ù. ÇÑ ¿¬±¸¿¡¼­´Â ÀÌ IncRNA panelÀ» ÀÌ¿ëÇÏ¿©, ³ú, Ç÷¾×, °ñ¼ö, À¯¹æ, Àå, ½ÅÀå, ÀÚ±Ã, Àü¸³¼±, ÇǺθ¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Á¶Á÷À¸·ÎºÎÅÍ ÆÄ»ýµÈ 60°³ÀÇ Àΰ£ ¾Ï ¼¼Æ÷ÁÖÀÎ NCI-60 ¾Ï¼¼Æ÷ÁÖÀÇ ¹ßÇöÀ» ºÐ¼®ÇÏ¿´´Ù. 1,700°³ÀÇ IncRNA Áß 97%°¡ NCI-60 ¾Ï¼¼Æ÷ÁÖ¿¡¼­ ÀçÇö¼º ÀÖ°Ô ¹ßÇöµÊÀ» ÀÌ panelÀ¸·Î È®ÀÎÇÏ¿´´Ù. ¶Ç ´Ù¸¥ ¿¬±¸¿¡¼­´Â IncRNA panelÀ» ÀÌ¿ëÇÏ¿©, Èæ»öÁ¾¿¡¼­ÀÇ Èæ»öÁ¾À» »ý¼ºÇÏ´Â ÁÖ¿ä ¸Å°³Ã¼¿¡ ´ëÇØ ºÐ¼®ÇÔÀ¸·Î½á, IncRNA SAMMSONÀÌ Èæ»öÁ¾À» °íµµ·Î ¹ßÇö½ÃÅ°´Â °ÍÀ» È®ÀÎÇÏ¿´°í ±×¿¡ ´ëÇÑ ÀÛ¿ë°ú ÈÄ¼Ó ½ÇÇèÀ» ÁøÇàÇß´Ù. ÃÖ±Ù¿¡ ÁøÇàµÈ ÇÑ ¿¬±¸¿¡¼­´Â somatic copy-number alterations (SCNA)°¡ ¾ÏÀ¯ÀüÀÚ È¤Àº Á¾¾ç ¾ïÁ¦ À¯ÀüÀÚ¿Í °°Àº ¿ªÇÒÀ» ÇÏ´Â IncRNA alternation¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» È®ÀÎÇϱâ À§ÇØ IncRNA panelÀ» °³¹ßÇÏ¿´À¸¸ç, ¾ÏÀ» À¯¹ßÇÏ´Â IncRNA È®ÀÎÇÏ´Â µ¥ À̸¦ È°¿ëÇÒ ¼ö ÀÖ´Ù.

Better biobanking with high-throughput qPCR
FFPE ¹æ¹ýÀ» ÀÌ¿ëÇϸé, »ý¹°ÇÐÀû »ùÇÃÀ» »ó¿Â¿¡¼­ ¿À·£ ½Ã°£ ½±°Ô º¸°üÇÒ ¼ö ÀÖÀ¸³ª, ¿À·£ °íÁ¤ ½Ã°£À¸·Î ÀÎÇØ, assay¸¦ ÅëÇÑ °ËÃâÀÌ ¾î·Á¿ï Á¤µµ·Î ÇÙ»êÀÌ ¼Õ»óµÉ ¼ö ÀÖ´Ù´Â ´ÜÁ¡ÀÌ ÀÖ´Ù. ÀÌ ÇѰ踦 ±Øº¹Çϱâ À§ÇØ ´ÙÄ«¶ó¹ÙÀÌ¿À°¡ Áö¿øÇÏ´Â ´ë·® qPCR ºÐ¼®ÀÌ °¡´ÉÇÑ SmartChip¢â systemÀ» Àû¿ëÇÒ ¼ö ÀÖ´Ù. º» Á¦Ç°À» ÀÌ¿ëÇÏ¸é »óÅ°¡ ÁÁÀº »ùÇÃ»Ó ¸¸ ¾Æ´Ï¶ó FFPE, µ¿°á º¸Á¸µÈ Á¶Á÷À» ´ë·®À¸·Î qPCR ºÐ¼®ÇÏ°íÀÚ ÇÒ ¶§ °¢°¢ÀÇ platformÀ» ÃÖÀûÈ­ÇÏ°í, hands-on time°ú ½Ã¾à »ç¿ë·®À» ¸ðµÎ ÃÖ¼ÒÈ­ÇÏ¿© ºÐ¼®ÇÒ ¼ö ÀÖ´Ù (±×¸²1).
Integrated Biobank of Luxembourg (IBBL)ÀÇ ¿¬±¸ÀÚµéÀº À̸¦ ÀÌ¿ëÇÑ FFPE »ùÇÃÀÇ ºÐ¼®¹ý¿¡ ´ëÇÑ ¿¬±¸¸¦ ÁøÇàÇÑ ¹Ù ÀÖ´Ù (Ammerlaan, W. et al.). Biobank¿¡¼­´Â ´Ù¾çÇÑ Àå±â¿Í Áúº´¿¡ ´ëÇÑ ¼ö¸¹Àº FFPE »ùÇÿ¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÉ ¼ö ÀÖµµ·Ï Áö¿øÇÏ°í ÀÖÀ¸³ª, »ùÇÃÀÇ °íÁ¤ ½Ã°£ÀÌ ¿À·¡µÊ¿¡ µû¶ó ÇÙ»êÀÌ ¼Õ»óµÇ¾î ¿¬±¸¿¡ ¾î·Á¿òÀÌ ÀÖ¾ú´Ù. À̸¦ À§ÇØ IBBL ¿¬±¸ÀÚµéÀº 6, 12, 23, 72½Ã°£µ¿¾È °íÁ¤µÈ ½ÅÀå°ú Àڱà FFPE »ùÇÃÀ» ÀÌ¿ëÇØ miRNA¿Í small nucleolar RNA (snoRNA)ÀÇ ¹ßÇöÀ» È®ÀÎÇÏ°íÀÚ Çß´Ù.
Small RNAÀÇ Å¸°ÙÀÌ ±²ÀåÈ÷ ¸¹±â ¶§¹®¿¡, IBBL ¿¬±¸ÀÚµéÀº 1,000°³ ÀÌ»óÀÇ miRNA¿Í snoRNA Ÿ°ÙÀ» ºÐ¼®ÇÒ ¼ö ÀÖ´Â SmartChip¢â Human miRNA Panel v3.0À» SmartChip¢â system¿¡ Àû¿ëÇÏ¿© ºÐ¼®ÇÏ¿´´Ù. ³í¹®ÀÇ ÀúÀÚ´Â °¢°¢ÀÇ chip 3°³·Î reference human total RNA¸¦ ºÐ¼®ÇÏ¿´À¸¸ç, °¢°¢À» ºñ±³ÇÏ¿© R2°ªÀÌ 0.98 ÀÌ»óÀ» ¾ò¾î ½ÇÇè ÀçÇö¼ºÀ» È®ÀÎÇÏ¿´´Ù. ÀÌ ÈÄ, ½ÅÀå°ú Àڱà »ùÇÃÀ» SmartChip¢â Human miRNA Panel v3.0¿¡¼­ ºÐ¼®ÇÏ¿© °íÁ¤ Á¶°Ç¿¡ µû¸¥ miRNA, snoRNA ¹ßÇö Â÷À̸¦ ºñ±³ÇÏ¿´À¸¸ç, snoRNA¿¡¼­ ¹ßÇöÀÌ ¾ÈÁ¤ÀûÀÌÁö ¾ÊÀ½À» È®ÀÎÇÏ¿´´Ù. ¿¬±¸ÀÚµéÀº SCARNA5, SNORA16A, SNORA44, SNORA61, ÃÑ 4°³ÀÇ snoRNA¸¦ ÀÌ¿ëÇÏ¿©, ¡°snoRNA CNRQ score¡±¸¦ °³¹ßÇÏ¿´À¸¸ç, À̸¦ È°¿ëÇϸé 6-12½Ã°£ ȤÀº 72½Ã°£ °íÁ¤µÈ »ùÇÃÀ» ±¸ºÐÇÒ ¼ö ÀÖ´Ù.
´Ù¸¸, ÀÌ ¹æ¹ýÀº SmartChip¢â system¿¡¼­ ´ÜÀÏ »ùÇÃÀ» ºÐ¼®ÇÏ´Â °æ¿ì¿¡¸¸ Àû¿ëÇÒ ¼ö Àֱ⿡, ÇѰ踦 ±Øº¹Çϱâ À§ÇØ ¡°snoRNA score¡±À» °³¹ßÇÏ¿´´Ù. À̸¦ ÀÌ¿ëÇϸé, 1,000¹ø ÀÌ»óÀÇ ºÐ¼®ÀÌ ÇÊ¿äÇÑ SmartChip¢â Human miRNA Panel v3.0 ´ë½Å, °íÁ¤ ½Ã°£¿¡ µû¶ó °ªÀÌ º¯È­ÇÏ´Â snoRNA¿Í °íÁ¤ ½Ã°£°ú °ü°è¾øÀÌ °ªÀÌ ÀÏÁ¤ÇÑ miRNA controlÀ» Æ÷ÇÔÇÏ´Â 24°³ÀÇ Å¸°Ù¸¸À¸·Îµµ ºÐ¼®ÀÌ °¡´ÉÇÏ´Ù. IBBL ¿¬±¸ÀÚµéÀº º¸´Ù ¸¹Àº 󸮷®À» ºÐ¼®Çϱâ À§ÇØ ¡°snoRNA score¡±À» SmartChip¢â system¿¡ Àû¿ë½ÃÄ×°í, 40°³ÀÇ »ùÇÃÀ» Á¤È®ÇÏ°Ô ºÐ¼®ÇÒ ¼ö ÀÖ¾ú´Ù.


±×¸² 1. Overview of the SmartChip¢â real-time PCR system.

Code

Á¦Ç°¸í

¿ë·®

640022

SmartChip¢â Real-Time PCR System

1 ´ë


[¿ø¹®] Using mRNA, miRNA, and lncRNA as biomarkers for cancer and other diseases
[Âü°í¹®Çå]
- Ammerlaan, W. et al. Small Nucleolar RNA Score: An Assay to Detect Formalin-Overfixed Tissue. Biopreserv. Biobank. 16, 467 (2018).
- Ammerlaan, W. & Betsou, F. Intraindividual Temporal miRNA Variability in Serum, Plasma, and White Blood Cell Subpopulations. Biopreserv. Biobank. 14:bio.2015.0125 (2016).
- Chen, X. et al. Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer. Clin. Cancer Res. 22:4505-4516 (2016).
- Choo, K. B., Soon, Y. L., Nguyen, P. N. N., Hiew, M. S. Y. & Huang, C.-J. MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J. Biomed. Sci. 21:95 (2014).
- Davis, T. E., Kis-Toth, K., Szanto, A. & Tsokos, G. C. Glucocorticoids suppress T cell function by up-regulating microRNA-98. Arthritis Rheum. 65:1882-1890 (2013).
- Ding, N. et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc. Natl. Acad. Sci. U. S. A. 112:15713-8 (2015).
- Kamhieh-Milz, J. et al. Differentially expressed microRNAs in maternal plasma for the noninvasive prenatal diagnosis of down syndrome (Trisomy 21). Biomed Res. Int. 2014 (2014).
- Leucci, E. et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature 531:518-522 (2016).
- Mestdagh, P. et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat. Methods 11:809-815 (2014).
- Mestdagh, P., Lefever, S., Volders, P. & Derveaux, S. Long non-coding RNA expression pro fi ling in the NCI 60 cancer cell line panel using. Sci. Data 1-6 doi:10.1038/sdata.2016.52 (2016).
- Nault, R., Fader, K. A. & Zacharewski, T. RNA-Seq versus oligonucleotide array assessment of dose-dependent TCDD-elicited hepatic gene expression in mice. BMC Genomics 16:373 (2015).
- Nguyen, P. N. N., Huang, C.-J., Sugii, S., Cheong, S. K. & Choo, K. B. Selective activation of miRNAs of the primate-specific chromosome 19 miRNA cluster (C19MC) in cancer and stem cells and possible contribution to regulation of apoptosis. J. Biomed. Sci. 24:20 (2017).
- Rothwell, D. G. et al. Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells. BMC Genomics 15:1129 (2014).
- Sardi, S. H., Glassner, B. J., Chang, J. R. & Yim, S. H. Identification of Critical Biomarkers Responsive to Anti-Autophagy Therapies for Pancreatic Ductal Adenocarcinoma through a Performance Analysis of miRNA Platforms. J. Bioanal. Biomed. 1:doi:10.4172/1948-593X.S10-001 (2014).
- Snyder, C. et al. Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry. Breast Cancer Res. Treat. 150:637-641 (2015).
- Ullmann, P. et al. Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production. Oncotarget7 (2016).
- Volders, P.-J. et al. Targeted genomic screen reveals focal long non-coding RNA copy number alterations in cancer. bioRxiv 113316:doi:10.1101/113316 (2017).
- Wei, N. et al. Oxidative stress diverts trna synthetase to nucleus for protection against dna damage. Mol. Cell 56:323-332 (2014).
- Wu, L. et al. Full-length single-cell RNA-seq applied to a viral human cancer: applications to HPV expression and splicing analysis in HeLa S3 cells. Gigascience 4:51 (2015).